In patients with NSCLC, it was reported that if TMB was equal to or greater than 10 mut/Mb, the combination of Nivolumab and Ipilimumab would have a better overall response (OR) regardless of PD-L1 expression [109]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.